Toxicity of Gentamicin and Tobramycin

James A. Koufman; James N. Thompson; Paul C. Levy; Darwin E. Zaske; Kent B. Crossley; Richard J. Strate; Craig R. Smith; James J. Lipsky; James Longstreth; Paul S. Lietman

doi:10.1056/NEJM198010233031715

Toxicity of Gentamicin and Tobramycin

James A. Koufman, James N. Thompson, Paul C. Levy, Darwin E. Zaske, Kent B. Crossley, Richard J. Strate, Craig R. Smith, James J. Lipsky, James Longstreth, Paul S. Lietman

Medicine - Veteran's Administration Medical Center

Research output: Contribution to journal › Letter › peer-review

Abstract

To the Editor: Gentamicin is well known to be primarily vestibulotoxic, ¹^,² although hearing loss may also occur. In this regard, some points should be made about the study by Smith et al. in the May 15 issue. First of all, no tests of vestibular function were carried out. Secondly, the ototoxic effects of the aminoglycosides may progress for weeks or months after cessation of therapy, i.e., hearing or vestibular function or both may continue to decline. In some cases, the first signs of vestibular or auditory dysfunction may occur after the completion of therapy. Therefore, a minimal follow-up period of.

Original language	English (US)
Pages (from-to)	1002-1003
Number of pages	2
Journal	New England Journal of Medicine
Volume	303
Issue number	17
DOIs	https://doi.org/10.1056/NEJM198010233031715
State	Published - Oct 23 1980

Publisher link

10.1056/NEJM198010233031715

Find It

Find It at U of M Libraries

Cite this

@article{0e4aee53e8f744799ece61de0a887cb5,

title = "Toxicity of Gentamicin and Tobramycin",

abstract = "To the Editor: Gentamicin is well known to be primarily vestibulotoxic, 1,2 although hearing loss may also occur. In this regard, some points should be made about the study by Smith et al. in the May 15 issue. First of all, no tests of vestibular function were carried out. Secondly, the ototoxic effects of the aminoglycosides may progress for weeks or months after cessation of therapy, i.e., hearing or vestibular function or both may continue to decline. In some cases, the first signs of vestibular or auditory dysfunction may occur after the completion of therapy. Therefore, a minimal follow-up period of.",

author = "Koufman, {James A.} and Thompson, {James N.} and Levy, {Paul C.} and Zaske, {Darwin E.} and Crossley, {Kent B.} and Strate, {Richard J.} and Smith, {Craig R.} and Lipsky, {James J.} and James Longstreth and Lietman, {Paul S.}",

year = "1980",

month = oct,

day = "23",

doi = "10.1056/NEJM198010233031715",

language = "English (US)",

volume = "303",

pages = "1002--1003",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "17",

}

TY - JOUR

T1 - Toxicity of Gentamicin and Tobramycin

AU - Koufman, James A.

AU - Thompson, James N.

AU - Levy, Paul C.

AU - Zaske, Darwin E.

AU - Crossley, Kent B.

AU - Strate, Richard J.

AU - Smith, Craig R.

AU - Lipsky, James J.

AU - Longstreth, James

AU - Lietman, Paul S.

PY - 1980/10/23

Y1 - 1980/10/23

N2 - To the Editor: Gentamicin is well known to be primarily vestibulotoxic, 1,2 although hearing loss may also occur. In this regard, some points should be made about the study by Smith et al. in the May 15 issue. First of all, no tests of vestibular function were carried out. Secondly, the ototoxic effects of the aminoglycosides may progress for weeks or months after cessation of therapy, i.e., hearing or vestibular function or both may continue to decline. In some cases, the first signs of vestibular or auditory dysfunction may occur after the completion of therapy. Therefore, a minimal follow-up period of.

AB - To the Editor: Gentamicin is well known to be primarily vestibulotoxic, 1,2 although hearing loss may also occur. In this regard, some points should be made about the study by Smith et al. in the May 15 issue. First of all, no tests of vestibular function were carried out. Secondly, the ototoxic effects of the aminoglycosides may progress for weeks or months after cessation of therapy, i.e., hearing or vestibular function or both may continue to decline. In some cases, the first signs of vestibular or auditory dysfunction may occur after the completion of therapy. Therefore, a minimal follow-up period of.

UR - http://www.scopus.com/inward/record.url?scp=0018940535&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018940535&partnerID=8YFLogxK

U2 - 10.1056/NEJM198010233031715

DO - 10.1056/NEJM198010233031715

M3 - Letter

C2 - 7412842

AN - SCOPUS:0018940535

SN - 0028-4793

VL - 303

SP - 1002

EP - 1003

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 17

ER -

Toxicity of Gentamicin and Tobramycin

Abstract

Publisher link

Find It

Other files and links

Fingerprint

Cite this